Pretreatment PSA levels affects the completion rate of Ra-223 treatment
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-86033-4
Abstract: The aim of this study was to review our initial experience of using radium 223 (Ra-223) for metastatic castration-resistant prostate cancer (CRPC) and to evaluate whether pretreatment PSA levels correlate with completion of Ra-223 treatment.… read more here.
Keywords: 223 treatment; completion; treatment; pretreatment psa ... See more keywords
Radium-223 treatment for metastatic prostate cancer: One year data in a single institution experience.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e17037
Abstract: e17037Background: Radium-223 treatment for bone only metastatic disease from metastatic castrate resistant prostate cancer (mCRPC) received approval from Scottish Medicines Consortium (SMC) on 13 O... read more here.
Keywords: prostate cancer; radium 223; 223 treatment;
Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13174346
Abstract: Simple Summary Radium-223 dichloride ([223Ra]RaCl2; Ra-223) is an alpha-emitting radiopharmaceutical treatment for patients with metastatic castration resistant prostate cancer (mCRPC) with predominantly bone metastases. While responses to chemotherapeutic and antihormonal mCRPC treatments can be assessed… read more here.
Keywords: response; 223 treatment; treatment; radium 223 ... See more keywords